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Background: In cystic fibrosis (CF), recurrent infections suggest impaired mucosal immunity but whether pro-
duction of secretory immunoglobulin A (S-IgA) is impaired remains elusive. S-IgA is generated following
polymeric immunoglobulin receptor (pIgR)-mediated transepithelial transport of dimeric (d-)IgA and repre-
sents a major defence through neutralisation of inhaled pathogens like Pseudomonas aeruginosa (Pa).
Methods: Human lung tissue (n = 74), human sputum (n = 118), primary human bronchial epithelial cells
(HBEC) (cultured in air-liquid interface) (n = 19) and mouse lung tissue and bronchoalveolar lavage were
studied for pIgR expression, IgA secretion and regulation.
Findings: Increased epithelial pIgR immunostaining was observed in CF lung explants, associated with more
IgA-producing plasma cells, sputum and serum IgA, especially Pa-specific IgA. In contrast, pIgR and IgA trans-
port were downregulated in F508del mice, CFTR-inhibited HBEC, and CF HBEC. Moreover, the unfolded pro-
tein response (UPR) due to F508del mutation, inhibited IgA transport in Calu-3 cells. Conversely, pIgR
expression and IgA secretion were strongly upregulated following Pa lung infection in control and F508del
mice, through an inflammatory host response involving interleukin-17.
Interpretation: A complex regulation of IgA secretion occurs in the CF lung, UPR induced by CFTR mutation/
dysfunction inhibiting d-IgA transcytosis, and Pa infection unexpectedly unleashing this secretory defence
mechanism.
Funding: This work was supported by the Forton's grant of the King Baudouin's Foundation, Belgium, the Fon-
dazione Ricerca Fibrosi Cistica, Italy, and the Fonds National de la Recherche Scientifique, Belgium.
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Cystic fibrosis (CF) is a lethal genetic autosomal recessive disease,
caused by mutations in the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) gene [1], which encodes for an anion channelexpressed in epithelial cells. Whereas all epithelia may be affected,
lung disease is mainly responsible for the morbidity and mortality of
patients with CF [2]. It is characterised by sticky mucus, chronic neu-
trophilic inflammation, recurrent opportunistic infections, and pro-
gressive formation of bronchiectasis. Pseudomonas aeruginosa (Pa) is
the most common bacteria found in the CF adult lung and is associ-
ated with a worsening of lung function and vital prognosis [3,4]. The
susceptibility to opportunistic Pa infection relates to impaired muco-
sal immunity underlying a permissive environment in CF airways. In
Research in context
Evidence before this study
Cystic fibrosis (CF) is a lethal genetic autosomal recessive dis-
ease, which is caused by mutations on cystic fibrosis transmem-
brane conductance regulator (CFTR) gene and mainly affects the
lungs. Lung disorder is characterised by airway inflammation
and Pseudomonas aeruginosa (Pa) infection that affects almost
70% of patients with CF and is associated with poor clinical out-
comes. Recurrent infections suggest impaired mucosal immu-
nity in patients and the secretion of immunoglobulin A (IgA) is
one of the defence mechanisms. IgA is transported across the
epithelium by a transcellular routing mediated by the poly-
meric immunoglobulin receptor (pIgR). In the bronchial lumen,
secretory IgA binds antigens and pathogens, and neutralises
them through the so-called immune exclusion. pIgR has been
studied in several chronic respiratory diseases, where its
expression is downregulated. However, no data is available in
CF. Previous studies reported increased IgA concentrations in
serum or bronchoalveolar lavage of patients with CF. Con-
versely, decreased IgA secretion was described in CF saliva and
in gastric luminal fluid.
Added value of this study
A multimodal approach was designed to assess epithelial trans-
porter and IgA immunity in the CF lung through lung tissue,
sputum, serum and primary epithelial cell cultures, as well as
CF mice. Systematic analyses of pIgR expression and IgA pro-
duction/secretion were performed in the different models
(steady state, upon CFTR dysfunction, or upon infection). We
observed increased pIgR expression and IgA production in the
human CF lung. While CFTR dysfunction per se leads to downre-
gulation of pIgR expression and IgA transcytosis, through acti-
vation of endoplasmic reticulum stress, chronic lung Pa
infection is associated with an upregulation of pIgR-mediated
IgA secretion through a host inflammatory response involving
interleukin-17.
Implications of all the available evidence
This study reconciled previous data by showing a complex
interplay between epithelial cells, B cells, and bacteria (Pa),
which connects CFTR dysfunction, unfolded protein response,
and a (Th17) host innate immune response to IgA secretion in
the lung. However, we observed in our study that a local spe-
cific humoral response to Pa leads to increased Pa-specific IgA
in chronically infected patients in both sputum and serum.
These measurements could provide a diagnostic tool for Pa
chronic infection in the lungs of patients with CF.
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ensure frontline defence against pathogens through mechanical and
immune barrier functions. In addition to mucociliary clearance, the
epithelium can sense and respond to pathogens, and is able to secrete
several antimicrobial molecules and cytokines/chemokines (tumour
necrosis factor-a (TNF-a), interleukin-8 (IL-8/CXCL8) and interleu-
kin-1b (IL-1b)) in order to recruit or activate innate immune cells
and, if required, to support activation of adaptative immunity. In CF,
multiple aspects of those mechanisms are impaired including muco-
ciliary clearance or production of antimicrobial proteins [5]. In addi-
tion, some studies suggest an imbalance between Th1 and Th2
responses, patients with CF with chronic Pa infection displaying a
Th2-dominated response, while Th1 response against Pa was relatedto a better outcome [6,7]. This immune response is accompanied by
increased Pa-specific immunoglobulin (Ig) G antibodies in the serum
from infected patients with CF [8], as well as by an increased local
production of Pa-specific IgA [9,10].
IgA exerts antimicrobial, antiviral, as well as anti-inflammatory
activities. Polymeric  mainly dimeric (d-)  IgA, produced by sube-
pithelial plasma cells, is transported into secretions by polymeric
immunoglobulin receptor (pIgR)-mediated transcytosis. After bind-
ing of d-IgA, the pIgR/d-IgA complex is sent to the apical pole where
the extracellular part of the receptor  called secretory component
(SC)  is cleaved, releasing SC bound to IgA to form secretory IgA (S-
IgA), as well as free SC [11]. At the epithelial surface, S-IgA may neu-
tralise antigens and pathogens through so-called immune exclusion.
In addition, SC itself may contribute to these anti-microbial and anti-
inflammatory functions [12,13], particularly by inhibiting the activity
of pro-inflammatory molecules such as IL-8/CXCL8, and by protecting
S-IgA from proteolytic degradation [14,15]. pIgR expression has been
studied in several chronic respiratory diseases [1618], where it is
downregulated, while no data is available in CF. Previous studies
reported increased IgA concentrations in serum [19] or bronchoal-
veolar lavage (BAL) of patients with CF [20], as well as increased free
SC in CF sputum [21]. Conversely, decreased IgA secretion was
described in CF saliva and in gastric luminal fluid [22,23].
This study was designed to assess epithelial pIgR and IgA immu-
nity in the CF lung through a multimodal approach including lung tis-
sue, sputum, serum and primary epithelial cell cultures, as well as
mice harbouring the F508del CFTR mutation (F508del mice) and
CFTR inhibition in primary epithelial cell cultures. We demonstrate
that pIgR/SC expression and IgA production are increased in the
human CF lung. While CFTR dysfunction per se leads to downregula-
tion of pIgR expression and IgA transcytosis, through activation of
endoplasmic reticulum (ER) stress, chronic lung Pa infection is associ-
ated with an upregulation of pIgR-mediated IgA secretion through a
host inflammatory response involving interleukin-17 (IL-17).
Methods
Patients
Lung tissue were obtained from 74 patients, which included
explants obtained from 36 patients with end-stage CF disease com-
pared with lung tissue from 38 control patients undergoing lung sur-
gery for a solitary lung tumour (n = 32) or unused lung donors (n = 6).
Sputum and serum were obtained from 118 subjects, with 67
patients with CF at stable state compared with 51 age-matched con-
trol subjects with no clinical evidence of lung disease and normal
lung function. 25 patients were enrolled for cell culture, which
included seven control subjects (undergoing lung resection surgery
for a solitary lung tumour) and 18 patients with severe CF (undergo-
ing lung resection surgery for transplantation) (Table 1). Patients
with CF were classified according to their state of infection by Pa as
follows; 1) chronic infection, when having more than 50% of months,
when samples had been taken, positive in a 12-months period, 2)
intermittent infection, when 50% or less months, when samples had
been taken, positive in a 12-months period, 3) free of infection, when
there was no growth of Pa in the last 12 months, and 4) never
infected, when Pa was never isolated in culture. Among Pa-never
infected patients, eight out of ten were infected by other bacteria
(such as Staphylococcus aureus, Achromobacter, or Burkholderia spe-
cies) and two patients were infected by Aspergillus fumigatus.
Immunohistochemistry for human and mouse pIgR, and human IgA
Lung samples were fixed in 4% formaldehyde and embedded in
paraffin wax. Paraffin lung sections (5 mm-thick) were deparaffinised
in toluene and rehydrated through a graded series from methanol to
Table 1
Patient characteristics.
Controls Patients with CF All
Lung tissue series Subjects, n 38 36 74
Sex, F/M 21/17 20/16 41/33
Age, years 58 § 14 31 § 9 45 § 18
Genotype, F508del homozygous/F508del heterozygous/other mutations NA 22/10/4 NA
FEV1, % predicted (n = 68) 94 § 18 24 § 8 60 § 38
Sputum and serum series Subjects, n 51 67 118
Sex, F/M 35/16 36/31 71/47
Age, years 31 § 10 34 § 11 33 § 11
BMI, kg/m2 23 § 5 22 § 3 22 § 4
Genotype, F508del homozygous/F508del heterozygous/other mutations NA 36/24/7 NA
FEV1, % predicted 100 § 9 67 § 23 81 § 25
VC, % predicted 102 § 10 87 § 19 93 § 17
Pa infection status, C/I/F/N [3] NA 33/12/12/10 NA
Human-derived epithelial cells series Subjects, n 7 18 25
Sex, F/M 1/6 9/9 10/15
Age, years 62 § 8 35 § 12 43 § 16
Genotype, F508del homozygous/F508del heterozygous/other mutations NA 9/7/2 NA
FEV1, % predicted (n = 16) 97 § 14 31 § 20 48 § 34
Subjects, n (pIgR expression) 6 8 14
Subjects, n (UPR activation) 8 10 18
Subjects, n (Pa supernatant stimulation) 0 5 5
Subjects, n (IL-17 stimulation) 0 6 6
Definition of abbreviations: CF, cystic fibrosis; F, female; M, male; FEV1, forced expiratory volume in the first second; NA, not applicable; BMI, body mass index; VC,
vital capacity; Pa, Pseudomonas aeruginosa; C, chronically infected by Pa; I, intermittently infected by Pa; F, free of Pa infection; N = never infected by Pa; pIgR, poly-
meric immunoglobulin receptor; UPR, unfolded protein response. N is specified when data are missing.
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retrieval treatment using cooker pressure treatment during 5 min at
a pressure of 15 psi. Endogenous peroxidase, biotin, and streptavidin
sites were inactivated by hydrogen peroxide, biotin, and avidin solu-
tions or Bloxall (Vector Laboratories Inc., USA), as appropriate. Non-
specific protein binding sites were blocked with 5% bovine serum
albumin or horse serum (Bio-Rad, USA) in tris-buffered saline (TBS)
for 1 h, according to the secondary antibody. Rabbit polyclonal anti-
human pIgR (1 mg/mL; home-made Lp877), mouse anti-human IgA
(4 mg/mL; Thermo Fisher Scientific, Germany), or goat anti-mouse
pIgR (R&D Systems, UK) were incubated overnight at 4°C. After
washes with TBS 0.1% Tween 20, sections were incubated with goat
anti-rabbit IgG (1:3000; Sigma-Aldrich, USA)  followed by streptavi-
din-horseradish peroxidase (HRP) amplification , horse anti-mouse
Ig (ImmPRESSTM Reagent) or mouse anti-goat IgG (1:100; Sigma-
Aldrich), respectively. Revelation was performed by using 3,30-Diami-
nobenzidine (Sigma-Aldrich). Sections were counterstained with
Hematoxylin (Sigma-Aldrich) and coverslipped. Slides were scanned
using Leica SCN400 (Leica, UK) before selecting the ten preserved
fields. Quantification was done with Leica software and expressed as
percentage of positive area for pIgR expression and for IgA immunos-
taining as the number of IgA positive cells per mm2.
Dual immunohistochemistry for IgA and cluster of differentiation (CD)
138, and for CD3 and RAR-related orphan receptor (ROR)gt
As previously, unstained paraffin sections were deparaffinised,
rehydrated, and subjected to antigen retrieval. Endogenous peroxi-
dase activity was blocked by incubation in Bloxall (Vector lab, USA)
for 15 min and 0.3% hydrogen peroxide in TBS 5% goat serum
(Abcam) for 30 min respectively. Each section was subjected to two
sequential stainings, each including a blocking with TBS 5% goat
serum followed by primary antibody incubation and corresponding
secondary HRP-conjugated polymer antibody (Invitrogen). Mouse
anti-human IgA (Thermo Fisher Scientific) and rabbit anti-CD138
(Acris, Germany), or rabbit anti-CD3 (Cell Signaling, USA) and mouse
anti-RORgt (Sigma) were successively used as primary antibody.Each HRP-conjugated polymer mediated the covalent binding of a
different fluorophore using tyramide signal amplification, as previ-
ously described [24]. Finally, sections were counterstained with
Hoechst (Thermo Fisher Scientific) and mounted with fluorescence
mounting medium (Dako, USA). As negative controls, we used corre-
sponding control isotypes diluted at the same concentration as
related primary antibody. Images were acquired with Panoramic
P250 Flash III slide scanner (3DHistech, Hungary). Quantification of
the CD3 and RORgt co-staining was performed with Author software
(Visiopharm) and was expressed as the number of positive cells per
mm2.
Basal cell isolation
The bronchial section was digested by pronase E from Streptomy-
ces griseus 1 mg/mL (Sigma-Aldrich) in Roswell Park Memorial Insti-
tute (RPMI) medium (Lonza, Belgium) supplemented with 200 U/mL
penicillin and 200 mg/mL streptomycin (Lonza) overnight at 4°C.
Cells were labelled with anti-CD151 conjugated with phycoerythrin
(Clone 14A2.H1, BD Biosciences) and anti-CD142 conjugated with
allophycocyanin (Clone HTF1, Miltenyi Biotec, Netherlands) antibod-
ies after blocking with FcR Blocking Reagent (Miltenyi Biotec) and
dead cells discrimination by Fixable Viability Stain 450 (BD Bioscien-
ces, USA). Cell sorting was performed with a FACSAria cell sorter (BD
Biosciences). Basal cells (CD151+/CD142+) were selected and seeded
in a 75 cm2 cell culture flask in bronchial epithelial basal medium
(BEBM) (Lonza), supplemented with 200 U/mL penicillin and 200 mg/
mL streptomycin (Lonza) (as well as PrimocinTM100 mg/mL (Invitro-
Gen, France) for CF cells), bovine serum albumin 1.5 mg/mL (Sigma-
Aldrich) and retinoic acid 100 mM (Sigma-Aldrich). Cells were cul-
tured at 37°C and 5% CO2 to reconstitute a primary bronchial epithe-
lium. When reaching 90% confluency, cells were trypsinised and
100,000 cells were seeded in 0.33 cm2 insert with 0.4 mm polyester
membrane pore (Corning, USA) in submerged condition for
1015 days. Then air-liquid interface (ALI) condition was applied for
two weeks in BEBM:Dulbecco's Modified Eagle Medium (DMEM)
(Lonza) 1:1 supplemented as pure BEBM.
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Primary human bronchial epithelial cells (HBEC) were treated
after culture for two weeks in ALI condition with 25mL of CFTR inhib-
itors (GlyH-101 or PPQ-102) (CF Foundation) (1, 5, 10, 20 mM), or
25 mL of Pa supernatant, at the apical pole for 48 h. Basal media, api-
cal washes, and cell lysates (for western blot or reverse transcription
and real-time polymerase chain reaction (RT-qPCR)) were then har-
vested. HBEC cultures were also treated for 48 h with increasing
doses of IL-17 (10, 20, 40 ng/mL). Basal media, apical washes, and cell
lysates (for western blot or RT-qPCR) were then collected and har-
vested.
For the transcytosis assay of d-IgA, after two weeks in ALI condi-
tion, 1 mg/mL d-IgA was added at basolateral pole for 72 h, and S-IgA
was measured by sandwich Enzyme Linked Immunosorbent Assays
in the apical wash (300mL phosphate-buffered saline).
Pa supernatant preparation and stimulation
Pa mucoid clinical strain was processed according to Massion and
colleagues to obtain Pa supernatant [25]. Briefly, Pa mucoid clinical
strain was seeded in Trypticone Soy Broth medium (BD, USA) and
incubated during 72 h, at 37°C. Then, bacteria culture was centrifuged
at 10,000 g during 50 min, at 4°C. Supernatant was filtered (0.2 mm)
and stored at -80°C. After two weeks in ALI condition, ALI-HBEC were
stimulated with 25 mL of Pa supernatant at apical pole for 48 h. Ster-
ile phosphate-buffered saline was used as control condition. Basal
media, apical washes, and cell lysates (for western blot or RT-qPCR)
were then harvested.
Calu-3 cell culture
Calu-3 cells (passages 1015) were cultured at 37°C and 5% CO2 in
a RPMI medium (Lonza), supplemented with 10% foetal bovine
serum, 200 U/mL penicillin and 200 mg/mL streptomycin (Lonza).
Cells were maintained in a 75 cm2 cell culture flask and split when
they reached 90% confluence. For unfolded protein response (UPR)
activation, Calu-3 cells were stimulated with thapsigargin (Sigma-
Aldrich) (0.2, 0.5, 1, 2 mM) or tunicamycin (Sigma-Aldrich) (2, 5, 10,
20 mg/mL), diluted in dimethyl sulfoxide (DMSO), during 6 h or 24 h.
DMSO was used as control condition. Media and cell lysates (for
western blot or RT-qPCR) were then harvested. For transcytosis assay
of d-IgA, Calu-3 cells (50,000 per insert) were seeded in 0.33 cm2
insert with 0.4 mm polyester membrane pore (Corning). After they
reached confluency, they were stimulated with 10 mg/mL tunicamy-
cin and 1 mg/mL d-IgA was added at basolateral pole for 48 h. DMSO
was used as control condition. Basal media and apical washes or
media were then collected. Calu-3 cell cultures were also treated for
48 h with increasing doses of IL-17 (5, 10, 20 ng/mL). Media and cells
lysates were then collected and harvested.
Sputum and serum collection, and processing
Sputum from patients with CF was obtained during a physiother-
apy session while sputum from healthy subjects was induced by
using the method of Pizzichini and colleagues, with minor modifica-
tions [26]. Sputum induction was achieved with an aerosol of hyper-
tonic saline generated by the NE-U17 ultrasonic nebulizer (Omron).
Healthy subjects equipped with a nose clip, inhaled increasing con-
centrations of saline (3, 4, and 5%) for 7 min each through a mouth-
piece. We then asked subjects to rinse their mouth or swallow to
minimise contamination with saliva. Finally, we invited them to
cough sputum into a sterile container. Collected sputum was diluted
1:10 (w:v) in phosphate-buffered saline with 10 U/mL DNase (Pulmo-
zyme 2500 U/2.5 mL  Roche, USA) and incubated under agitation,
during 30 min, at 37°C. Then, it was filtered with 48 mm pore nylonfilter (Prosep, Belgium) and centrifuged at 450 g, during 5 min. Neu-
trophil elastase activity was measured in supernatant. Remaining
supernatant was treated with PMSF Protease Inhibitor 2% v:v in order
to inactivate elastase and was stored at -80°C. Cells were processed
for cytospin (fixed in methanol and staining by Diff-Quick method
(Kwik-DiffTM Stains, Thermo Fisher Scientific) and epithelial contami-
nation was assessed. The blood was centrifuged at 650 g for 20 min,
the serum was collected, and stored at -80°C.
F508del mice and model of Pa lung infection with Pa-coated beads
Mice (FVB/129) homozygous for the F508del mutation (F508del
mice, kindly received from Dr T. Leal, UCLouvain Brussels, Belgium)
and wild-type littermates (WT mice) were housed in a specific patho-
gen free animal facility, in ventilated cages. 15 F508del mice and 15
WT received no treatment (eight females and seven males in each
group). In parallel, nine F508del (eight females and one male) and six
WT (four females and two males) mice were instilled with agarose
beads, coated with a clinical strain of Pa (isolated from a patient with
CF). Sterile beads were used to instil seven F508del (four females and
three males) and eight WT (three females and five males), as control.
Beads were prepared according to Martin and colleagues [27]. Dis-
solved agarose (coloured with Indian ink) (Type XII, Sigma-Aldrich)
was mixed with mineral oil (Sigma-Aldrich) at 50°C, and with
around 109 colony-forming units of Pa in culture. This mix was
cooled down with ice while mixing for 20 min. After rinsing by cen-
trifugations at 4°C, beads were sieved twice to obtain a homogenous
solution of 300 to 400 mm beads, a size considered optimal to pene-
trate the lower airways, but not the alveoli. In order to control the
bacterial load, beads and Pa culture were spread on agar-agar and
counted after incubation during 24 h at 37°C. A volume of 40 mL of
beads solution at 5% in phosphate-buffered saline (sterile beads or
Pa-coated) was instilled in mouse trachea after anaesthesia with
Ketamine 15 mg/mL (Nimatek 100 mg/mL Eurovet, Netherlands)
and Xylazine 2 mg/mL (Rompun 2%, Bayer, GmbH D24106, Ger-
many) at 100 mL/10 g body weight. Eventual respiratory stress could
appear after instillation and therefore mice were closely monitored
and received oxygen supplementation if needed. After 15 days, mice
were sacrificed, BAL was performed, and lungs were collected for
immunochemistry, RT-qPCR and western blot, as well as blood to
obtain serum.
Western blot for pIgR/SC and (phospho-)eukaryotic initiation factor 2a
((P-)eIF2a)
Cells were lysed with Laemmli’s Blue. After boiling for 5 min,
lysates were separated by 12% sodium dodecyl sulfate-polyacryl-
amide gel and proteins were transferred to a nitrocellulose mem-
brane. After blocking with TBS 5% bovine serum albumin, the
membrane was incubated with rabbit anti-pIgR (1:6000; homemade
Lp877), rabbit anti-GAPDH (1:3000; Sigma-Aldrich), mouse anti-
eIF2a (1:2000; Cell Signaling), rabbit anti-P-eIF2a (1:1000; Cell Sig-
naling), and mouse anti-b-actin (1:1000; Sigma-Aldrich) overnight at
4°C, then with goat anti-rabbit IgG (1:2000; Cell Signaling) or anti-
mouse IgG (1:5000; Sigma-Aldrich) for 1 h at room temperature.
Detection of immunoreactivity was performed with the ECLTM Prime
Western Blotting Detection chemiluminescence reagent (Amer-
shamTM ECL, GE Healthcare, UK) blot and quantification was per-
formed by using Quantity One software.
Enzyme Linked Immunosorbent Assays for SC, S-IgA, S-IgM, specific IgA
to Pa and IL-17
SC, S-Ig, and total Ig concentrations were measured in HBEC apical
washes, sputum supernatants or serums, in plates coated with anti-
SC (1:2000; Ch606), anti-IgA (1:1000; ACP17) or anti-IgM (Sigma-
A.M. Collin et al. / EBioMedicine 60 (2020) 102974 5Aldrich) as capture antibody. After washes, samples and standard
incubated 2 h, at 37°C, and detection was performed with biotiny-
lated anti-SC (1:4000; Ch606)  followed by Streptavidin-HRP ampli-
fication  or HRP-linked anti-IgA (1:5000; Sigma-Aldrich) or anti-
IgM (1:5000; Sigma-Aldrich).
In sputum supernatants, specific IgA to Pa were determined by
coating 2.25 mg of antigens from serotypes 001-015 (Statens Serum
Institute, Denmark) and detection was performed with the antibody
mentioned above, and IL-17 was measured by Duoset (R&D Systems).
In mouse BAL and serum, concentrations of mouse total IgA, as
well as (only in BAL) mouse S-IgA and mouse SC, were measured.
Plates were coated with anti-mouse IgA (1:1000; Sigma-Aldrich) or
anti-mouse SC (1:200; R&D Systems). After blocking, samples and
standard (IgA k myeloma (Sigma-Aldrich) or pure BAL) were loaded
and incubated 2 h, at 37°C. Immunodetection was carried out by
using biotinylated anti-mouse IgA (SYnAbs, Belgium) and Streptavi-
din-HRP amplification. For mouse SC, samples and standard (R&D
Systems) were coated in plates and incubated overnight at 4°C.
Mouse SC was captured with goat anti-mouse SC (R&D Systems) and
detected by biotinylated anti-goat IgG (Sigma-Aldrich) and Streptavi-
din-HRP amplification.Reverse transcription and real-time polymerase chain reaction
After extraction, ribonucleic acid (RNA) was reverse-transcribed
with RevertAid H minus Reverse transcriptase kit (Thermo FisherFig. 1. pIgR expression is increased in airway epithelium from control and patients with CF a
one representative control and one representative patient with CF. (b) pIgR expression in
Mann-Whitney test). (c) pIgR expression in small airways from 19 patients with CF, as com
(corrected for housekeeping genes) in lung homogenates from 15 patients with CF, compared
tile ranges. pIgR, polymeric immunoglobulin receptor; CF, cystic fibrosis. Scale bar, 100 mm.Scientific, UK) with 0.3 mg of random hexamer, 20 U of RNase inhibi-
tor, and 1 mM of each dNTP following the manufacturer’s protocol in
a thermocycler (Applied Biosystems). For the expression measure-
ment, the reaction mix contained 2.5 mL of complementary desoxyri-
bonucleic acid diluted 10-fold, 200 nM of each primer (Table S1), and
2x iTaq UniverSybr Green Supermix (Bio-Rad) in a final volume of
20 mL. The cycling conditions were 95°C for 3 min followed by 40
cycles of 95°C for 5 s and 60°C for 30 s. To control the specificity of
the amplification products, a melting curve analysis was performed.
Copy number was calculated from the standard curve. Expression
levels of target genes were normalised to the geometric mean of the
values for the housekeeping genes (ribosomal protein S13, S18 and
L27 in human lung tissue and primary HBEC, S18 and hypoxanthine-
guanine phosphoribosyltransferase 1 in Calu-3, and TATA-box bind-
ing protein, hypoxanthine-guanine phosphoribosyltransferase 1 and
tyrosine 3-monooxygenase/ tryptophan 5-monooxygenase activation
protein zeta in mouse tissue).Transmission electron microscopy
ALI-HBEC were fixed overnight at 4°C in 2.5% glutaraldehyde BEBM:
DMEM 1:1 (Lonza), supplemented as mentioned before, washed in
cacodylate buffer (pH 7.4) and postfixed twice in 1% osmium tetroxide
(and 1.5% ferrocyanide) for 1 h. Then, cells were stained with 1% uracyl
acetate for 1 h at room temperature, dehydrated in ethanol and embed-
ded in epoxy resin (Agar 100 resin; Agar Scientific, UK). Quantificationt the protein level. (a) pIgR immunostaining in a large airway and in a small airway from
large airways from 30 patients with CF, as compared with 30 controls (***p < 0.0001,
pared with 11 controls (***p = 0.0003, Mann-Whitney test). (d) PIGR mRNA expression
with 16 controls (p= 0.1490, Mann-Whitney test). Bars indicate median and interquar-
6 A.M. Collin et al. / EBioMedicine 60 (2020) 102974of the ER area was performed with ImageJ software. Results were
expressed as the percentage of ER area.Statistical analysis
GraphPad Prism 8.0.2 software (GraphPad Inc., USA) and SPSS
(IBM) were used for statistical analysis. Normality of the data distri-
bution was first assessed. Comparisons between two groups were
performed using an unpaired Student’s t test, except when data dis-
tribution were not normal. In such case, comparisons between two
groups were performed using the Mann-Whitney U-test, whereas
comparisons between more than two groups were performed using
the Kruskal-Wallis test followed by a Dunn’s post-hoc test or Fried-
man test in case of paired values. Comparisons were considered as
significant if p-value was under 0.05.Ethics statement
All patients received information and signed a written consent to
the study protocol, which was approved by our local clinical ethical
committee (Ref. protocol “CLARA” 2005/22SEP/149  update 29/11/
2016, S51577 S52174 S55877) and CPP Ile de France II #1072 for lung
tissue samples, Ref. 2015/09Jan/014 for sputum samples). Murine
experiments were approved by our local Faculty Ethical committee
(Ref. 2018/UCL/MD/04).Results
Upregulation of epithelial pIgR and IgA expression in the human CF lung
pIgR expression was increased in the bronchial epithelium from
patients with CF, compared with controls, in both large and small air-
ways (Fig. 1ac) while no significant difference was observed at the
mRNA level in lung homogenates (Fig. 1d).
As an increased number of lymphoid aggregates was confirmed in
our CF lungs, compared with controls (Fig. S1), IgA immunostaining
was carried out on lung tissue, and confirmed a large increase in the
number of IgA+ cells in CF lungs in subepithelial areas (Fig. 2a) and in
the surrounding submucosal glands (Fig. 2b). A dual immunostaining
for IgA and CD138 indicated that >70% of IgA+ cells consisted of IgA+
plasma cells (Fig. 2c).Upregulation of total and Pa-specific IgA in human CF sputum
Despite raised neutrophil elastase activity in sputum from patients
with CF (Fig. S2a), which is able to cleave IgA and SC [28], the concen-
tration of IgA was increased in sputum and serum from patients with
CF, compared with controls, especially in chronically Pa infected
patients (Fig. 3ab). Never Pa infected patients were nevertheless
infected with other bacteria (such as Staphylococcus aureus, Achromo-
bacter, or Burkholderia species) or Aspergillus fumigatus (in eight and
two out of ten patients, respectively). A similar increase was observed
for IgM (Fig. S2b), also secreted following pIgR-mediated transport. In
addition, a trend for increased S-IgA and no change for SC (Fig. 3a)
were noticed. Of note, higher concentrations of IgA and SC were mea-
sured in sputum from F508del homozygous patients when compared
with patients without this mutation (Fig. S2cf).
In addition, a Pa-specific IgA response was observed in sputum
and serum from patients with CF, chronically or intermittently
infected with Pa (Fig. 3cd), and in patients carrying at least one
F508del mutation (Fig. S2agh).Downregulation of pIgR expression following CFTR dysfunction in the
human bronchial epithelium
In order to avoid the major risk of infection of primary CF HBEC, air-
way basal cells were sorted (by using CD142 and CD151 staining), and
cultured in ALI for two weeks to reconstitute in vitro a differentiated CF
bronchial epithelium [29]. In contrast to tissue data, a reduced pIgR
expression was observed in CF HBEC, compared with the epithelium
derived from control lungs both at protein (Fig. 4a) and mRNA level
(Fig. 4b). In addition, the CF-derived epithelium displayed strong
decreases in SC and S-IgA release in the apical washes (Fig. 4cd). To
confirm this negative link between CFTR dysfunction and pIgR expres-
sion, control HBEC were treated at 2 weeks in ALI culture with increas-
ing concentrations of two CFTR inhibitors (GlyH-101 and PPQ-102).
After 48 h of treatment, a dose-dependent decrease in pIgR/SC produc-
tion and SC release in apical washes was observed (Fig. 4ef).
Downregulation of pIgR expression and IgA secretion following CFTR
dysfunction in F508del mice
In order to confirm pIgR downregulation in “sterile” environment
upon CFTR dysfunction in vivo, we studied pIgR expression in
F508del mice. A decreased pIgR expression was observed, as com-
pared with WTmice (Fig. 5a), as well as a lower concentration of total
IgA in BAL (Fig. 5b). As in human lung, S-IgA in BAL (Fig. 5c) and Pigr
mRNA expression in lung homogenates were not significantly
changed (Fig. 5d).
UPR is activated in CF-derived HBEC and F508del mice, and affects SC
secretion
To explore the mechanism of pIgR downregulation observed upon
CFTR dysfunction, in both human CF HBEC and F508del mice, we
hypothesised that the ER stress and UPR could be involved. Indeed,
F508del mutation has been associated with an accumulation of mis-
folded proteins in the ER, resulting in ER stress and UPR activation
[30]. UPR activation assessed by the mRNA ratio of active, spliced/
unspliced, XBP-1 was confirmed in F508del mouse lungs (Fig. 6a),
which received no treatment. A trend was also observed in the recon-
stituted epithelium from patients with CF (most of them harbouring
at least one copy of the F508del mutation) as compared with controls
(Fig. 6b). In addition, ER stress was also evidenced by transmission
electron microscopy showing dilated ER cavities in CF, while this fea-
ture was absent in control HBEC (Fig. 6c). Therefore, we stimulated
UPR in Calu-3 cells (by thapsigargin or tunicamycin), an epithelial
cell line which stably expresses pIgR at high level, to evaluate
whether this regulates pIgR expression. UPR activation leading to
phosphorylation of eIF2a (Fig. 6de), increased spliced/unspliced
XBP1 mRNA ratio (Fig. 6f) and dose-dependently decreased pIgR pro-
tein expression (Fig. 6g) and SC release (Fig. 6h). In addition, d-IgA
transcytosis was impaired in Calu-3 cells treated with tunicamycin
(Fig. 6i). These data indicate that UPR activation per se (or that follows
ER stress) could recapitulate the downregulation of pIgR expression
and IgA transport observed in CF cell cultures and in CF mouse lungs.
Upregulation of pIgR expression and (S-)IgA production upon Pa
infection
In order to reconcile the apparent discrepancy between upregu-
lated pIgR expression in human CF lungs and its downregulation
upon CFTR dysfunction in HBEC and in F508del mice, we reasoned
that the negative CFTR-pIgR link could be overcome during lung
infection with Pa. We observed that WT mice instilled with Pa-coated
beads displayed increased pIgR expression in the airway epithelium
compared with sterile beads (Fig. 7a). In addition, a strong upregula-
tion of IgA and S-IgA concentrations was observed in BAL upon Pa
Fig. 2. Patients with CF display increased IgA+ cells number. (a) IgA staining in the subepithelial area from one representative control and one representative patient with CF and
number of IgA+ cells in the subepithelial area from 30 patients with CF, as compared with 30 controls (***p < 0.0001, Mann-Whitney test). (b) IgA staining in the glandular area
from one representative control and from one representative patient with CF and number of IgA+ cells in the glandular area from 18 patients with CF, as compared with 27 controls
(***p < 0.0001, Mann-Whitney test). (c) Identification of plasma cells (CD138+ cells (orange)) producing IgA (green; arrows) in the subepithelial area from one patient with CF. Bars
indicate median and interquartile ranges. IgA, immunoglobulin A.
A.M. Collin et al. / EBioMedicine 60 (2020) 102974 7infection both inWT and F508del mice (Fig. 7bc), associated with an
increase in PIGRmRNA expression (Fig. 7d).
Pa infection upregulates pIgR expression through an indirect mechanism
involving IL-17
To address the mechanisms by which Pa could upregulate pIgR
expression and IgA secretion, CF HBEC were incubated with the
supernatant of a Pa clinical strain culture. Only marginal and not
significant changes in PIGR mRNA expression, pIgR protein, SC
release and d-IgA transcytosis were observed in CF-derived cells
treated for 48 h with Pa supernatant (Fig. S3). An indirect mecha-
nism was then explored by looking at the inflammatory response
induced by Pa infection. In particular, we evaluated IL-17 as it is
reportedly increased upon Pa infection, and it is able to upregu-
late PIGR mRNA expression in intestinal cells [31,32]. An induc-
tion of Il17 mRNA expression was noticed in the lungs from mice
instilled with Pa-coated beads, compared with mice instilled with
sterile beads (Fig. 8a). While IL-17A upregulation was not recapit-
ulated in sputum or lung tissue from patients with CF (Fig. 8bc),
immune cells producing IL-17 (RORgt+ cells, including CD3+
RORgt+ Th17 cells) [33,34] were increased in subepithelial areas
of patients with CF, compared with controls (Fig. 8d), as well as
in total lung tissue (Fig. S4a). When CF-derived cells were stimu-
lated by increasing concentrations of IL-17A, we observed a dose-
dependent increase in pIgR expression (Fig. 8e), associated with a
trend to increased PIGR mRNA expression, SC release and d-IgAtranscytosis (Fig. 8fh), which did not influence UPR activation
through XBP-1 splicing (Fig. 8i). Upregulated PIGR mRNA was also
measured Calu-3 cells stimulated by IL-17A (Fig. S4bd). As
shown in CF-derived HBEC, no influence on UPR activation
through XBP-1 splicing was observed upon IL-17A treatment (Fig.
S4e). These data suggest that Pa infection could stimulate pIgR
expression and S-IgA production in the CF lung by activating an
inflammatory host response that involves IL-17.
Discussion
This study shows that epithelial pIgR expression, IgA produc-
tion, and IgA+ B cells are all upregulated in the CF lung, sputum
and serum. This IgA response includes specific antibodies to Pa
which represents a major opportunistic bacterium in this disease.
Secondly, experiments in airway epithelial basal/stem cell-derived
cultures from CF lungs and in F508del mice revealed a constitu-
tive downregulation of pIgR/SC production and d-IgA transcytosis,
as recapitulated by adding CFTR inhibitors in control cells. This
negative CFTR-pIgR pathway involved UPR activation following
the ER stress observed in CF. Finally, an in vivo model of chronic
lung infection by Pa-coated microbeads enabled to identify that
infection could restore pIgR expression and IgA production in the
lungs from F508del mice, through an IL-17 inflammatory host
response (Fig. 9).
In contrast to previous data in COPD or chronic rhino-sinusi-
tis, this study shows that bronchial pIgR expression is
Fig. 3. IgA and Pa-specific IgA concentrations are increased in sputum and serum from patients with CF. (a) IgA concentration in sputum from 51 controls and 65 patients with CF
(**p = 0.0092, unpaired Student’s t-test), distributed following Leeds criteria (***p < 0.001, **p < 0.01, Kruskal-Wallis test followed by Dunn’s test); S-IgA concentration in sputum
from 51 controls and 65 patients with CF (p = 0.1146, unpaired Student’s t-test); SC concentration in sputum from 51 controls and 65 patients with CF (p = 0.2516, unpaired Student’s
t-test). (b) IgA concentration in serum from 51 controls and 66 patients with CF (***p = 0.0006, unpaired Student’s t-test), distributed following Leeds criteria (***p < 0.001, Kruskal-
Wallis test followed by Dunn’s test). (c) Pa-specific IgA concentration in sputum from 51 controls and 65 patients with CF (*p = 0.0107, unpaired Student’s t-test), distributed follow-
ing Leeds criteria (***p < 0.001, *p < 0.05, Kruskal-Wallis test followed by Dunn’s test). (d) Pa-specific IgA concentration in serum from 51 controls and 66 patients with CF
(***p = 0.0003, unpaired Student’s t-test), distributed following Leeds criteria (***p < 0.001, **p < 0.01, *p < 0.05, Kruskal-Wallis test followed by Dunn’s test). Bars indicate mean
and standard deviation or median and interquartile ranges (Leeds distribution). IgA, immunoglobulin A; Pa, Pseudomonas aeruginosa; CF, cystic fibrosis; S-IgA, secretory immuno-
globulin A; SC, secretory component; C, chronically infected by Pa; I, intermittently infected by Pa; F, free of Pa infection; N, never infected with Pa.
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Fig. 4. pIgR expression and SC/S-IgA release are downregulated in ALI-HBEC derived from patients with CF and in control ALI-HBEC upon CFTR inhibition. (a) Representative west-
ern blot for pIgR in CF ALI-HBEC, compared with control ALI-HBEC and its pIgR-SC/GAPDH expression quantification in eight CF ALI-HBEC, compared with six control ALI-HBEC
(**p = 0.0027, Mann-Whitney test). (b) PIGR mRNA expression (corrected for housekeeping genes) in eight CF ALI-HBEC, compared with six control ALI-HBEC (*p = 0.0426, Mann-
Whitney test). (c) SC release in apical washes of eight CF ALI-HBEC, compared with six control ALI-HBEC (*p = 0.0293, Mann-Whitney test). (d) After transcytosis assay, S-IgA release
in apical washes of eight CF ALI-HBEC, compared with six control ALI-HBEC (*p = 0.0127, Mann-Whitney test). (e) Representative western blot for pIgR in control ALI-HBEC, treated
48 h with increasing concentrations of GlyH-101 and PPQ-102 or DMSO as control and its pIgR-SC/GAPDH expression quantification in three control ALI-HBEC. (f) Concentration of
SC released in apical washes of three control ALI-HBEC, treated 48 h with increasing concentrations of GlyH-101 and PPQ-102 or DMSO as control. Bars indicate median and inter-
quartile ranges. pIgR, polymeric immunoglobulin receptor; SC, secretory component; S-IgA, secretory immunoglobulin A; ALI-HBEC, human bronchial epithelial cells in air-liquid
interface; CF, cystic fibrosis.
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increased in this disease, as previously observed in COPD [36].
Whereas decreased SC concentration in saliva from patients with
CF was previously reported [37], Marshall et al. observed an
increased concentration and altered glycosylation of SC in CF
sputum [21]. Our study could reconcile the apparent discrepancy
between previous studies regarding IgA [2023], by suggesting
that IgA upregulation may selectively occur in the lungs (but not
in the digestive tract) as those are the target of acquired bacte-
rial infection (e.g. Pa) in CF. This increased IgA response is par-
ticularly noticed in patients with severe disease, and includes
the production of serum/systemic and respiratory/secretory Pa-
specific IgA [9,3842]. Our study robustly confirms increased IgAlevels in CF airways, as well as increased serum IgA, and that
this response includes a specific reactivity to Pa at both levels.
A major finding of this study is that epithelial pIgR expression
and IgA transport are disrupted in primary cultures of HBEC from
patients with CF, as well as in the lung from F508del mice. In
human lung homogenates, Pigr gene expression was not affected,
maybe due to the large amount of non-pIgR expressing cell types
into the lung. On the contrary, the use of CF-derived HBEC
showed impaired pIgR expression when cultivating in the
absence of inflammatory stimulus and allows to distinguish slight
difference (notably for PIGR mRNA levels). In vitro experiments
using selective CFTR inhibitors could confirm that CFTR dysfunc-
tion induces pIgR protein downregulation and defective pIgR
Fig. 5. pIgR expression and IgA secretion are decreased in airways from F508del mice. (a) pIgR immunostaining in an airway from one representative WT mouse and from one rep-
resentative F508del mouse and quantification in airways from 15 F508del mice, as compared with 15 WT mice (*p = 0.0344, Mann-Whitney test). (b) IgA concentration, normalised
for total protein content, in BAL from ten F508del mice, compared with ten WT mice (**p = 0.0058, Mann-Whitney test). (c) S-IgA concentration, normalised for total protein content
in BAL from ten F508del mice, compared with ten WT mice (p = 0.6305, Mann-Whitney test). (d) Pigr mRNA expression (corrected for housekeeping genes) in lung homogenates
from ten F508del mice, compared with ten WT mice (p = 0.6842, Mann-Whitney test). Bars indicate median and interquartile ranges. pIgR, polymeric immunoglobulin receptor;
IgA, immunoglobulin A; WT, wild-type; S-IgA, secretory immunoglobulin A; BAL, bronchoalveolar lavage. Scale bar, 50mm.
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mice. F508del mutation, which was also carried by most of our
patients with CF from whom cells were derived, is associated
with improper folding and accumulation of the CFTR protein in
the ER. Therefore, we hypothesised and confirmed that ER stress
and subsequent UPR activation could represent a mechanism
involved in pIgR downregulation, in line with previous reports in
short-term cultures of CF-derived cells and in a CF cell line
[30,43]. We could also demonstrate UPR activation through XBP-1
splicing in the lungs from F508del mice even in the absence of
infection. Furthermore, our data show that UPR activation in epi-
thelial cells induces a downregulation of pIgR/SC production as
well as of d-IgA transcytosis. In addition, it has been shown that
UPR activation in CF not only fails to resolve the ER stress but
also sensitises the inflammatory response to Toll-like receptor
stimulation [30]. Interestingly, pIgR downregulation (among sev-
eral other proteins) was also linked to UPR activation in the con-
text of ulcerative colitis [44], whereas another recent study
showed that mice with a restricted deletion of XBP-1 in the intes-
tinal epithelium (thus enable to develop UPR to counteract ER
stress in these cells) display T cell-independent accumulation of
IgA+ plasma cells and increased IgA secretion, which mediates
protection against spontaneous enteritis [45]. In line with the lat-
ter, our data further show that UPR activation itself disrupts epi-
thelial pIgR expression and that lungs from patients with CF (and
presumably increased ER stress) display increased numbers of
mucosal IgA+ plasma cells. Taken together, our study and
these data globally indicate that ER stress and UPR pathway rep-
resent key regulatory checkpoints of IgA production at mucosal
surfaces.
Infection with Pa, the most common bacteria in adult patients
with CF [3,46], was studied as a plausible mechanism that could
underlie the upregulation of IgA in the human (infected) CF
lung, and which is absent in cell cultures and CFTR-mutated
mice. The model of chronic Pa lung infection favours the reten-
tion of the bacteria in the airways and reproduces some features
of the CF lung disease such as strong neutrophilic inflammationand peribronchial lymphoid aggregates [47,48]. Only a slight
increased inflammatory score in FVB F508del mice was demon-
strated, in contrast with C57BL/6J CFTR-KO mice showing some
lymphoid aggregates [49,50]. When compared with the same
genetic background, CFTR-KO and F508del mice display the same
phenotype and, until now, no diseased lung phenotype related
to CFTR misfolding has been observed in F508del mice [51].
F508del mice (on FVB/129 background) classically display a
reduction in body weight, CF nasal electrophysiological profile
and tendency to intestinal mucus obstruction, associated with
normal survival [50,52]. Variabilities between murine models are
mostly attributed to the strain background [52]. We show that
Pa infection overcomes the (mutated) CFTR-driven inhibitory
pathway on the pIgR, thereby unleashing IgA production in the
CF lung. This phenomenon occurs independently from UPR regu-
lation, as Pa infection further increases ER stress and UPR activa-
tion [43,53], and activates the host inflammatory response that
includes the release of IL-17. This cytokine is able to stimulate
pIgR expression in airway epithelial cells as previously shown in
intestinal epithelial cells [32]. Interestingly, Th17-mediated
responses (through IL-17A production) were shown to upregu-
late pIgR expression in the airway epithelium and IgA/M concen-
trations in BAL from mice [54]. Other inflammatory cytokines
such as IL-1b and TNF-a, which are also upregulated upon Pa
infection and able to stimulate pIgR transcription in airway cell
lines [55,56], could also be implicated. Similarly, the observation
of increased levels of IgA in sputum from never infected patients
(Fig. 3a) suggests that other opportunistic bacteria (e.g., Staphylo-
coccus aureus, Burkholderia cepacia) could drive similar mecha-
nisms as those evidenced with Pa. However, increased
concentration of IL-1b and TNF-a as well as IL-8, and neutro-
philic inflammation has been demonstrated in BAL of young
infants, without the presence of detectable pathogens, suggesting
“sterile inflammation” [57,58]. But these statements remain con-
troversial [59,60]. We could not assess this in our patients with
CF cohort (for lung tissues and sputum) since these adult
patients (although few were never infected by Pa) were carriers
Fig. 6. UPR is activated in CF-derived human HBEC and in lungs from F508del mice at baseline and it downregulates SC secretion in Calu-3 cells. (a) Xbp1s/Xbp1u mRNA ratio (cor-
rected for housekeeping genes) in lung from ten F508del mice receiving no treatment, compared with ten WT mice (*p = 0.0133, Mann-Whitney test). (b) XBP1s/XBP1u mRNA ratio
(corrected for housekeeping genes) in HBEC (cultured in sterile condition) from nine patients with CF, compared with seven controls (p = 0.1738, Mann-Whitney test). (c) Transmis-
sion electron microscopy in HBEC (cultured in sterile condition) from one control and from one patient with CF and quantification of ER (arrows) surface in one control and from
one patient with CF (**p = 0.0094, unpaired Student’s t-test). (d) Representative western blot for eIF2a, P-eIF2a and pIgR in Calu-3 cells treated with increasing concentrations of
thapsigargin, tunicamycin or DMSO as control condition. (e) Quantification of P-eIF2a/eIF2a protein expression in Calu-3 cells after treatment with increasing concentrations of
thapsigargin and tunicamycin, compared with DMSO as control condition (n = 3). (f) XBP1s/XBP1u mRNA ratio (corrected for housekeeping genes) in Calu-3 cells treated increasing
concentrations of thapsigargin and tunicamycin or DMSO as control condition (n = 3). (g) Quantification of pIgR/b-actin expression in Calu-3 cells after treatment with increasing
concentrations of thapsigargin and tunicamycin, compared with DMSO as control condition (n = 3). (h) SC secretion upon treatment with increasing concentrations of thapsigargin
and tunicamycin, compared with DMSO as control condition (n = 3). (i) After transcytosis assay, S-IgA release upon thapsigargin treatment (*p = 0.0286, Mann-Whitney test) (n = 4).
Bars indicate median and interquartile ranges, except for (c) (mean and standard deviation). UPR, unfolded protein response; XBP1s, spliced X-box binding protein 1; XBP1u,
unspliced X-box binding protein 1; eIF2a, eukaryotic initiation factor 2 a; P-eIF2a, phospho-eukaryotic initiation factor 2 a; pIgR, polymeric immunoglobulin receptor; SC, secretory
component; S-IgA, secretory immunoglobulin A; Tha, thapsigargin; Tun, tunicamycin. Scale bar, 500 nm.
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Fig. 7. pIgR expression and (S-)IgA secretion are upregulated in lungs frommice infected with Pa. (a) pIgR immunostaining in an airway from one representative WTmouse instilled
with sterile beads or Pa-coated beads and quantification (in the airway epithelium surrounding the beads) in five WT mice instilled with Pa-coated beads, compared with four WT
mice instilled with sterile beads (*p = 0.0159, Mann-Whitney test). (b) IgA concentration, normalised for the total protein content, in BAL from six WT mice instilled with Pa-coated
beads, compared with eight WT mice instilled with sterile beads (*p = 0.0200, Mann-Whitney test) and from nine F508del mice instilled with Pa-coated beads, compared with seven
F508del mice instilled with sterile beads (***p = 0.0007, Mann-Whitney test). (c) S-IgA concentration, normalised for the total protein content, in BAL from six WT mice instilled
with Pa-coated beads, compared with eight WT mice instilled with sterile beads (**p = 0.0013, Mann-Whitney test) and from nine F508del mice instilled with Pa-coated beads, com-
pared with seven F508del mice instilled with sterile beads (*p = 0.0164, Mann-Whitney test). (d) Pigr mRNA expression (corrected for housekeeping genes) in lungs from six WT
mice instilled with Pa-coated beads, compared with eight WT mice instilled with sterile beads (*p = 0.0134, Mann-Whitney test). Bars indicate median and interquartile ranges.
pIgR, polymeric immunoglobulin receptor; Pa, Pseudomonas aeruginosa; S-IgA, secretory immunoglobulin A; SC, secretory component; BAL, bronchoalveolar lavage. Scale bar,
100mm.
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mation (in CF animal models and CF samples) showed the poten-
tial responsibility of hypoxic injury, resulting in necrosis, IL-1a
release and sterile neutrophilic inflammation [61]. The possible
induction of IL-1b and activation of NF-kB by IL-1a might be
responsible of pIgR expression early in patients with CF, even
before infection detection. As mentioned before, despite showing
no CF-like lung phenotype, F508del mice develop a minor but
spontaneous inflammation in the lungs. However, we could
notice that pIgR expression was still affected in this model
although the decrease was less marked than in cellular model.
This could be due to isolation of cells from inflammatory micro-
environment.
The preserved IgA response to pathogens was already sug-
gested by increased Pa-specific IgA antibodies in saliva and nasal
secretions from patients with CF [9], as well as by increased
serum specific IgG correlated to the presence of Pa in the sinuses
[62]. Such Pa sinusitis may precede intermittent lung infection,
suggesting that paranasal sinuses may represent a bacterial reser-
voir able to re-contaminate the patient after lung eradication
[63]. Pa-specific IgA in saliva was also assessed as a predictor of
Pa chronic infection [64,65]. Similarly, we observed in our study
that a local specific IgA response to Pa is consistently observed in
chronically infected patients, both in serum and sputum secre-
tions. Whether those IgA assays could provide the added value to
IgG antibodies and bacteriology for the diagnosis of Pa (chronic)
infection should be further studied in larger and multicentric
clinical cohorts.
One limitation of our study first relates to the end-stage status
of patients with CF recruited for tissue samples (lung explants). It
is however remarkable that sputum data from a large spectrum
of disease severity retrieved consistent findings, indicating that S-IgA upregulation encompasses the full spectrum of adult patients
with CF. Second, we encountered difficulties to observe differen-
ces in IL-17 levels (and did not observe changes in PIGR expres-
sion despite SC alterations) in lung homogenates. While increased
number of IL-17-producing cells were shown in CF, we could not
confirm increased IL-17 expression or secretion possibly as a
result of the dilution of the signal by the nature of the sample
(tissue homogenate). As mentioned above, while pIgR mRNA
changes were observed in isolated broncho-epithelial cells, no
difference was measured in lung homogenates, possibly due to a
similar dilution of the signal. In addition, this study did not
directly assess whether IgA plays a protective role in the lung
from patients. It was reported that overglycosylation of SC in CF
reduces its capacity to bind and neutralise IL-8/CXCL8, hence
favouring neutrophilic inflammation [21]. It is further possible
that accumulated S-IgA in the bronchial lumen (Fig. 2b), following
increased production and impaired mucociliary clearance, could
form immune complexes that  instead of being eliminated to
achieve immune exclusion  activate FcaRI-bearing phagocytes
[66]. Thus, the exact role of upregulated lung IgA responses dur-
ing CF should be further investigated. Finally, pIgR dysregulation
in the absence of lung infection was assessed in F508del patients
but the state of IgA secretion (through pIgR) remains unclear in
non-F508del patients and could be further addressed in a dedi-
cated study of such patients even though these mutations are
rarer and most patients suffer from early infection. It would be
interesting to also address this point in CFTR-KO mice, compared
to F508del mice.
In conclusion, this study in CF reveals a complex interplay
between epithelial cells, B cells, and bacteria (Pa), which connects
CFTR dysfunction, UPR activation, and a (Th17) host innate immune
response to IgA secretion in the lung.
Fig. 8. IL-17 is increased in lungs from mice infected with Pa and upregulates pIgR expression in ALI-HBEC derived from patients with CF. (a) Il17 mRNA expression (corrected for
housekeeping genes) in lungs from six WT mice instilled with Pa-coated beads, compared with eight WT mice instilled with sterile beads (*p = 0.0373, Mann-Whitney test). (b) IL-
17 concentration in sputum from 65 patients with CF, compared with 51 controls (p = 0.3088, Mann-Whitney test). (c) IL17 mRNA expression (corrected for housekeeping genes) in
lung homogenates from 15 patients with CF, compared with 16 controls (p = 1.0000, Mann-Whitney test). (d) RORgt staining (and CD3) in the subepithelial area from one represen-
tative control and one representative patient with CF, and number of RORgt+ cells (filled and no-filled arrows), including CD3+ RORgt+ cells (filled arrows), in the subepithelial area
from 9 patients with CF, as compared with 10 controls (*p = 0.0279, p = 0.0551,Mann-Whitney test). (e) Representative western blot for pIgR in CF ALI-HBEC, treated with increasing
concentrations of IL-17 and its pIgR-SC/GAPDH expression quantification in six CF ALI-HBEC, treated with increasing concentrations of IL-17 (*p = 0.0437, Friedman test). (f) PIGR
mRNA expression (corrected for housekeeping genes) in five CF ALI-HBEC, treated with increasing concentrations of IL-17. (g) SC release by six CF ALI-HBEC, treated with increasing
concentrations of IL-17. (h) SC release by six CF ALI-HBEC, treated with increasing concentrations of IL-17. (i) XBP1s/XBP1u mRNA ratio (corrected for housekeeping genes) in five CF
ALI-HBEC, treated with increasing concentrations of IL-17. Bars indicate median and interquartile ranges. IL-17, interleukin 17; Pa, Pseudomonas aeruginosa; pIgR, polymeric immu-
noglobulin receptor; CF, cystic fibrosis; ROR, RAR-related orphan receptor; CD, cluster of differentiation; SC, secretory component; S-IgA, secretory immunoglobulin A; XBP1s/u,
spliced/unspliced X-box binding protein 1. Scale bar, 50mm.
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Fig. 9. Model of pIgR regulation in CF lung. First, accumulation of misfolded F508del-CFTR (CFTR*) is responsible for ER stress. Consequently, activation of UPR is able to downregu-
late SC and S-IgA secretion. Second, Pa infection modulates this pathway (orange arrows). Pa drives host IL-17 response which stimulates PIGR expression and further increases ER
stress and UPR activation.[43,53] In addition, if ER stress caused by Pa infection becomes insufficiently counterbalanced by UPR activation, it may contribute to IgA upregulation, as
previously shown.[45] CFTR, cystic fibrosis transmembrane regulator; UPR, unfolded protein response; SC, secretory component; S-IgA, secretory immunoglobulin A; d-IgA, dimeric
immunoglobulin A; Pa, Pseudomonas aeruginosa; IL-17, interleukin 17; pIgR, polymeric immunoglobulin receptor.
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